Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques

AIDS

Volumn 17, Issue 3, 2003, Pages 301-309

  Ferrantelli, Flavia ^a,b   Hofmann Lehmann, Regina ^a,b   Rasmussen, Robert A ^a,b   Wang, Tao ^a,b   Xu, Weidong ^a,b   Li, Pei Lin ^a,b   Montefiori, David C ^d   Cavacini, Lisa A ^b,c   Katinger, Hermann ^g   Stiegler, Gabriela ^f,g   Anderson, Daniel C ^e   McClure, Harold M ^e   Ruprecht, Ruth M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^g POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH   (Austria)

Author keywords

Maternal HIV transmission; Neutralizing monoclonal antibodies; Oral infection; Passive immunization; Pathogenic simian human immunodeficiency virus (SHIV); Post exposure prophylaxis; Rhesus macaques

Indexed keywords

EPITOPE; GLYCOPROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1B12; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST FEEDING; CHIMERA; CONTROLLED STUDY; DELIVERY; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFECTION PREVENTION; LYMPHOCYTE COUNT; NEWBORN; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROVOCATION TEST; PUERPERIUM; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME; VIREMIA; VIRUS TRANSMISSION;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL; CD4 LYMPHOCYTE COUNT; CHIMERA; DISEASE TRANSMISSION, VERTICAL; HIV INFECTIONS; IMMUNITY, CELLULAR; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MACACA MULATTA; PROSPECTIVE STUDIES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

EID: 0037436188     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200302140-00003     Document Type: Article

References (48)

1. Mandelbrot L, Burgard M, Teglas JP, Benifla JL, Khan C, Blot P, et al. Frequent detection of HIV-1 in the gastric aspirates of neonates born to HIV-infected mothers. AIDS 1999, 13: 2143-2149.
2. Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, Mwatha A, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1. JAMA 2000, 283:167-1174.
3. The Petra Study Team. The Petra trial: the efficacy of three short-course regiments of zidovudine and lamivudine (3TC) in preventing early and late transmission of HIV-1 from mother to child in an African setting: a randomized, double-blind placebo-controlled trial, conducted in South Africa, Tanzania and Uganda. Lancet 2002, 359:11 78-1186.
4. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal SHIV virus infection. Nat Med 2000, 6:200-206.
5. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, Smith BA, Baba TW, Liska V, et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 2001, 75:7470-7480.
6. Li JT, Halloran M, Lord CI, Watson A, Ranchalis J, Fung M, et al. Persistent infection of macaques with simian-human immunodeficiency viruses. J Virol 1995, 69:7061-7067.
7. Reimann KA, Li JT, Voss G, Lekutis C, Tenner-Racz K, Racz P, et al. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human virus in rhesus monkeys. J Virol 1996, 70:3198-3206.
8. Reimann KA, Li JT, Veazey R, Halloran M, Park IW,Karlsson GB, et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 1996, 70:6922-6928.
9. Shibata R, Maldarelli F, Siemon C, Matano T, Parta M, Miller G, et al. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing. J Infect Dis 1997, 176:362-373.
10. Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983, 2:1099-1102.
11. Roben R, Moore JP, Thali M, Sodroski J, Barbas III CF, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994, 68:4821-4828.
12. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996, 70:1100-1108.
13. Muster T, Steindle F, Purtscher M, Trkola A, Klima A, Himmler G, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993, 67:6642-6647.
14. Parker CE, Deterding LJ, Hager-Braun C, Binley JM, Schulke N, Katinger H, et al. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol 2001, 75:10906-10911.
15. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Ollman Saphire E, Binley JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001, 75:10892-10905.
16. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001, 17:1757-1765.
17. Xu W, Smith-Franklin BA, Li, P-L, Wood C, He J, Du Q, et al. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J Hum Virol 2001, 4:55-61.
18. Spouge JL. Statistical analysis of sparse infection data and its implication for retroviral treatment trials in primates. Proc Natl Acad Sci USA 1992, 89:7581-7585.
19. Crawford JM, Earl PL, Moss B, Reimann KA, Wyand MS, Manson KH, et al. Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J Virol 1998, 73:10199-10207.
20. Rasmussen RA, Hofmann-Lehmann R, Montefiori DC, Li P-L, Liska V, Vlasak J, et al. DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. J Med Primatol 2002, 31:40-60.
21. Hofmann-Lehmann R, Swenerton RK, Liska V, Lutz H, McClure HM, Ruprecht RM. Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems. AIDS Res Hum Retroviruses 2000, 16:1247-1257.
22. Bures R, Gaitan A, Zhu T, Graziosi C, McGrath KM, Tartaglia J, et al. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2000, 16:2019-2035.
23. Larsson M, Jin X, Ramratnam B, Ogg GS, Engelmayer J, Demoitie MA, et al. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1 positive individuals. AIDS 1999, 13:767-777.
24. Smith BA, Gartner S, Liu Y, Perelson AS, Stilianakis NI, Keele BF, et al. Persistance of infectious HIV on follicular dendritic cells. J Immunol 2001, 166:690-696.
25. Karlsson GB, Halloran M, Schenten D, Lee J, Racz P, Tenner-Racz K, et al. The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques. J Exp Med 1998, 188:1159-1171.
26. Etemad-Moghadam B, Sun Y, Nicholson EK, Karlsson GB, Schenten D, Sodroski J. Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo. J Virol 1999, 88:73-79.
27. DeMaria MA, Casto M, O'Connell M Johnson RP, Rosenzweig M. Characterization of lymphocyte subsets in rhesus macaques during the first year of life. Eur J Haematol 2000, 65:245-257.
28. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M Fox CH, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993, 362:355-358.
29. Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, Melroe H, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996, 274:985-989.
30. Ferrantelli F and Ruprecht RM. Neutralizing antibodies against HIV - back in the major leagues? Curr Opin Immunol 2002, 14:495-502.
31. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6:207-210.
32. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001, 75:8340-8347.
33. Parren PW, Wang M, Trkola A, Binley JM, Purtscher M, Katinger H, et al. Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. J Virol 1998, 72:10270-10274.
34. Collins JJ, Sackie DM, Johnson GR. Immunotherapy of murine leukemia. IX. The requirement for the Fc portion of antibody for successful passive serum therapy of Friend leukemia virus-induced disease. Virology 1983, 126:259-266.
35. Kohl S, Loo LS. Protection of neonatal mice against herpes simplex virus infection: probable in vivo antibody-dependent cellular toxicity. J Immunol 1982, 129:370-376.
36. Ahmad A, Menezes J. Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J 1996, 10:258-266.
37. Hezareh M, Hessell AJ. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol 2001, 75:12161-12168.
38. Jenkins M, Mills J, Kohl S. Natural killer cytotoxiclty and antibody-dependent cellular cytotoxicity of human immunodeficiency virus-infected cells by leukocytes from human neonates and adults. Pediatr Res 1993, 33:469-474.
39. Ljunggren K, Moschese V, Broliden PA, Giaquinto C, Quinti I, Fenyo EM, et al. Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis 1990, 161:198-202.
40. Broliden K, Sievers E, Tovo PA, Moschese V, Scarlatti G, Broliden PA, et al. Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1 infected mothers and their children. Clin Exp Immunol 1993, 93:56-64.
41. Cavacini LA, Samore MH, Gambertoglio J, Jackson B, Duval M, Wisenewski A, et al. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120, AIDS Res Hum Retroviruses 1998, 14:545-550.
42. Wolfe EJ, Cavacini LA, Samore MH, Posner MR, Kozial C, Spino C, et al. Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1. Clin Pharmacol Ther 1996, 59:662-667.
43. Schaad UB, Gianella-Borradori A, Perret B, Imbach P, Morell A. Intravenous immune globulin in symptomatic paediatric human immunodeficlency virus infection. Eur J Pediatr 1988, 147:300-303.
44. The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991, 325:73-80.
45. Armbruster C, Stiegler GM, Vcelar BA, Jäger W, Michael NL, Vetter N, et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 2002, 16:227-233.
46. Stiegler G, Armbruster C, Vcelar B, Stoiber H, Kunert R, Michael NL, et al. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS 2002, 16:2019-2025.
47. Chen X, Scala G, Quinto I, Liu W, Chun TW, Justement JS, et al. Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. Nat Med 2001, 7:1225-1231.
48. Shibata R, Igarasgu T, Haigwood N, Buckler-White A, Ogert R, Ross W, et al. Neutralizing antibody directed against the HIV-1 envelope glycoproteln can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999, 5:204-210.